Aerie Pharmaceuticals Inc Logo Image

Aerie Pharmaceuticals Inc

Aerie Pharmaceuticals Inc Banner Image

Most Recent Annual Report

2018 Annual Report and Form 10K

Aerie Pharmaceuticals Inc
Order Free Hardcopy

You can request a free hardcopy of this report mailed to you by clicking the button below.

Add Annual Report

Archived Annual Reports

  • Aerie Pharmaceuticals Inc
  • Aerie Pharmaceuticals Inc

About Aerie Pharmaceuticals Inc

201-500 Employees
Based in Durham, North Carolina

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its product candidates include Rhopressa, which is a once-daily eye drop that reduces intraocular pressure (IOP) in patients with glaucoma or ocular hypertension and is in Phase III registration trials; and Roclatan, a once-daily eye drop to reduce IOP that has completed Phase IIb clinical trial in patients with open-angle glaucoma and ocular hypertension.

Ticker:
AERI
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Drug Manufacturers - Major (See More Drug Manufacturers - Major Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol